Abstract
Intensive antithrombotic therapies reduce ischaemic complications of percutaneous coronary intervention for ST-segment elevation myocardial infarction, but at a cost of increased bleeding. Bivalirudin consistently reduces haemorrhagic risk, even with potent new oral antiplatelet drugs and contemporary interventional practice. The benefit of bivalirudin must, however, be balanced against increased risk of early subacute stent thrombosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
